Incurin Tablets For the treatment of hormone-responsive urinary incontinence due to sphincter mechanism incompetence in female dogs. The active ingredient in Incurin, estriol, is a naturally occurring, short-acting estrogen. Estriol can help restore estrogen levels in spayed dogs to support a dog’s natural processes for maintaining urethral tone for urinary control. It differs from most other estrogens because it binds with estrogen receptors for a short time.
Incurin Tbalets are indicated for the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.
Incurin Tablets is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.
The dose of Incurin Tablets is not dependent upon body weight.
All dogs should receive an initial dose of 2 mg Incurin Tablets (2 tablets) orally once per day for a minimum of 14 days.
After urinary incontinence is controlled, the lowest effective daily dose of Incurin Tablets should be determined by decreasing the dose in a step-wise manner from 2 mg once daily (2 tablets) to 1 mg once daily (1 tablet), then 0.5 mg once daily (1/2 tablet) depending upon the response of the individual dog.
There should be a minimum of 7 days between each dose adjustment. After the lowest daily dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days. Dogs should not receive more than 2 mg Incurin Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin Tablets per day, the diagnosis should be re-assessed.
Not for human use. Keep out of the reach of children. Women who are of child-bearing age or those who are breastfeeding should use caution when administering Incurin Tablets. Wash your hands with soap and water after administration to avoid exposure to the drug. Consult a physician in case of accidental ingestion by humans.
Some estrogens have been associated with bone marrow changes and an increased risk of mammary tumors. However, target animal safety study results and foreign post-market pharmacovigilance data for Incurin Tablets have shown that estriol-treated dogs are at low risk for developing these conditions.
Evaluation factors contributing to urinary incontinence should be considered prior of administration of Incurin Tablets.
Do not use with other estrogens. The concomitant use of Incurin Tablets other estrogens has not been evaluated.
The concomitant use of Incurin Tablets with glucocorticoids has not been evaluated.
The use of Incurin Tablets in dogs with liver disease has not been evaluated. The safe use of Incurin Tablets has not been evaluated in intact female dogs, pregnant or lactating dogs, and dogs less than 1 year of age.